A Clinical Trial of Nemtabrutinib in Participants With Severe Kidney Disease (MK-1026-027)

StatusRecruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date changed from estimate of Sep 17, 2026 to Sep 8, 2026
  2. Recruitment opened Show 5 more changesShow less
    • Lead sponsor: Merck Sharp & Dohme LLC to Merck Sharp & Dohme LLC
    • Start date: Aug 17, 2026 to Sep 17, 2026
    • Study sites: 0 to 1
    • Secondary endpoints: details revised at 5 of 10 entries
    • Eligibility criteria expanded, about 5 words
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Merck (MSD)
410 trials monitored
See 27 trials at risk
The purpose of this study is to learn what happens to nemtabrutinib in a person's body when given to participants with severe kidney disease and to healthy participants.
Trial Details
NCT Number NCT07734610
Lead Sponsor Merck Sharp & Dohme LLC
Conditions
(from sponsor)		 Severe Renal Impairment, Healthy
Related terms Renal Insufficiency
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov